Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years

Kavasmaa, Outi T; Tyomkin, Dimitri B; Mehik, Aare; Parpala, Teija M; Tonttila, Panu; Paananen, Ilkka; Kunelius, Pekka; Vaarala, Markku H.; Ohtonen, Pasi; Hellström, Pekka

doi:10.1186/1477-7819-11-258

Cited by 5 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The changes could probably be largely rationalized by a complete change in the previous pool of PC patients, with a huge number of PSA-diagnosed early-onset PC patients (approximately a fourfold increase in patient numbers). PSA-tested patients were characterized by a low T stage and a low proportion of patients presenting with distant metastases [ 2 , 3 ]. According to the present results, in the pre-PSA year of 1980, about 15% of PC patients died in FI and NO during year 1 after diagnosis (somewhat less in SE and more in DK), 50% of patients died by year 5 and 65% died by year 10.…”

Section: Discussionmentioning

confidence: 99%

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

Zitricky

Försti

Hemminki

et al. 2023

Cancers

View full text Add to dashboard Cite

Background: The incidence of prostate cancer (PC) increased vastly as a result of prostate-specific antigen (PSA) testing. Survival in PC improved in the PSA-testing era, but changes in clinical presentation have hampered the interpretation of the underlying causes. Design: We analyzed survival trends in PC using data from the NORDCAN database for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-, 5- and 10-year relative survival and conditional relative survival over the course of 50 years (1971–2020). Results: In the pre-PSA era, survival improved in FI and SE and improved marginally in NO but not in DK. PSA testing began toward the end of the 1980s; 5-year survival increased by approximately 30%, and 10-year survival improved even more. Conditional survival from years 6 to 10 (5 years) was better than conditional survival from years 2 to 5 (4 years), but by 2010, this difference disappeared in countries other than DK. Survival in the first year after diagnosis approached 100%; by year 5, it was 95%; and by year 10, it was 90% in the best countries, NO and SE. Conclusions: In spite of advances in diagnostics and treatment, further attention is required to improve PC survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

Zitricky

Försti

Hemminki

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…With higher rates of opportunistic PSA screening, there has reportedly been a significant stage shift in PCa from locally, advanced metastatic PCa to early stage, lower volume PCa [ 11 ]. The NCRI reports a continued increase in T1 and T1c stages of PCa in the last decade but leveling off of the T2 cancer cases in line with the overall incidence [ 4 ].…”

Section: Discussionmentioning

confidence: 99%

Increasing detection of significant prostate cancer in younger men - ten year trends in prostate cancer risk profile in the Mid-west of Ireland

Bhatt

Kelly

Domanska

et al. 2017

CEJU

View full text Add to dashboard Cite

IntroductionAlthough PSA (prostate specific antigen) based screening for prostate cancer (PCa) is controversial, an increasing number of men are undergoing Transrectal Ultrasound Guided prostate biopsy (TRUSPB) through primary care-based PSA testing and referral to hospitals. The aim of our study was to investigate presenting risk profiles of PCa over the last decade in a cohort of men in Ireland and to examine any change in the same over this time period.Material and methodsThe hospital patient administration system was analysed for patients who underwent TRUSPB from January 2005 to December 2015. Clinically significant PCa was defined as Gleason score of 7 or above.ResultsComplete data was available on 2391 TRUSPB patients: number of biopsies increased by 53%, median age decreased by 0.9%, median PSA decreased by 6% (p = 0.001, ANOVA) and abnormal DRE increased by 9% (p = 0.001, chi square). Overall positive biopsy was 44% and significant cancer rate was 21%. There was a significant change in trend of detection (p = 0.02) with average annual increase in significant cancer of 3%. The median age of the significant cancer cohort reduced by 1% and the PSA at diagnosis reduced by 9%. In younger men (<50 years), the rate of significant cancer detection increased by 18%.ConclusionsSignificant PCa detection increased across all age groups but recently, a younger patient profile was diagnosed with high-grade disease. This paves the way for future research on early-onset PCa. Younger patients with significant disease would result in increasing number of patients being eligible for radical treatment with implications on health resource planning and provision.

show abstract

“…PC is usually asymptomatic at the early stage. If symptoms are present, they are often confused with normal signs of aging, which means that the condition remains undiagnosed in many cases 4 . Benign prostatic conditions, such as benign prostatic hyperplasia (BPH), may also be confused with PC because of the same symptoms 5 .…”

Section: Introductionmentioning

confidence: 99%

“…If symptoms are present, they are often confused with normal signs of aging, which means that the condition remains undiagnosed in many cases. 4 Benign prostatic conditions, such as benign prostatic hyperplasia (BPH), may also be confused with PC because of the same symptoms. 5 Therefore, discriminative diagnosis is required to distinguish these conditions precisely.…”

Section: Introductionmentioning

confidence: 99%

Circulating plasma miR222‐3P status and its potential diagnostic performance in prostate cancer

Heydari

Moudi

Sadeghi

et al. 2022

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background: Although studies suggest that miR222-3p is dysregulated in prostate cancer (PC) cells and tissues, the possible changes in the level of miR222-3p in the plasma samples of PC patients remained unclear. The present study aimed to evaluate the diagnostic value of the plasma miR222-3p expression level as a potential biomarker in PC, benign prostatic hyperplasia (BPH) and healthy people.Methods: Blood samples were collected from 100 adult males (54 patients with PC, 27 patients with BPH and 19 healthy individuals) referred to our affiliated hospital.The expression level of miR222-3p was evaluated using a quantitative reverse transcription-polymerase chain reaction. Receiver operating characteristic curves were used to evaluate miR222-3p diagnostic accuracy for discriminating between the PC, BPH and healthy individuals.Results: The expression level of miR222-3p was significantly higher in PC patients compared to healthy individuals as a fold change of 5.3 (p = 0.009), but not for BPH individuals. The diagnostic value of the plasma miR222-3p for discrimination of the PC patients from healthy individuals was reasonable [cut-off value (fold change relative to miR16-5p) = 1.69, area under the curve = 0.73, sensitivity = 0.75 and specificity = 0.74].Conclusions: Circulating plasma miR-222-3p significantly upregulated in PC patients, but not in BPH ones. Besides these preliminary results showed that miR222-3p has the potential to discriminate PC patients from healthy ones. Addittional studies with a larger sample size are required to confirm these data.

show abstract

Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years

Cited by 5 publications

References 22 publications

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

Increasing detection of significant prostate cancer in younger men - ten year trends in prostate cancer risk profile in the Mid-west of Ireland

Circulating plasma miR222‐3P status and its potential diagnostic performance in prostate cancer

Contact Info

Product

Resources

About